Organon & Co. (ticker OGN) adjusted its capital allocation strategy and dividend policies to prioritize debt reduction and balance sheet flexibility following its corporate spin-off from Merck. While management has balanced payouts to support long-term deleveraging goals, income-focused investors closely monitor its quarterly declarations, earnings reports, and cash flow conversion metrics to track dividend sustainability and historical adjustments.